News
By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new study into GLP-1 medicines after worrying ...
Wegovy, the ₹26K/month weight-loss jab, hits India with bold promises—from fat loss to heart health. But is this pharma fix a ...
Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster ...
Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...
NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...
The count-down's on for New Zealand chemist sales of weight-loss drug Wegovy. A pharmacist has told our newsroom the ...
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results